Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial.

Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, Lilac HA, Hall H, Klimov A, Fukuda K.

JAMA. 2000 Oct 4;284(13):1655-63.

PMID:
11015795
2.

Seasonal influenza vaccination of healthy working-age adults: a review of economic evaluations.

Gatwood J, Meltzer MI, Messonnier M, Ortega-Sanchez IR, Balkrishnan R, Prosser LA.

Drugs. 2012 Jan 1;72(1):35-48. doi: 10.2165/11597310-000000000-00000. Review.

PMID:
22191794
3.

Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.

Postma MJ, Jansema P, van Genugten ML, Heijnen ML, Jager JC, de Jong-van den Berg LT.

Drugs. 2002;62(7):1013-24. Review.

PMID:
11985488
4.

Influence of timing of seasonal influenza vaccination on effectiveness and cost-effectiveness in pregnancy.

Myers ER, Misurski DA, Swamy GK.

Am J Obstet Gynecol. 2011 Jun;204(6 Suppl 1):S128-40. doi: 10.1016/j.ajog.2011.04.009. Epub 2011 Apr 15. Review.

PMID:
21640230
5.

Economic evaluation of influenza vaccination. Assessment for The Netherlands.

Postma MJ, Bos JM, van Gennep M, Jager JC, Baltussen R, Sprenger MJ.

Pharmacoeconomics. 1999;16 Suppl 1:33-40. Review.

PMID:
10623374
6.

Is influenza-like illness a useful concept and an appropriate test of influenza vaccine effectiveness?

Thomas RE.

Vaccine. 2014 Apr 17;32(19):2143-9. doi: 10.1016/j.vaccine.2014.02.059. Epub 2014 Feb 28. Review.

PMID:
24582634
7.

Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.

Thommes EW, Kruse M, Kohli M, Sharma R, Noorduyn SG.

Hum Vaccin Immunother. 2017 Apr 3;13(4):867-876. doi: 10.1080/21645515.2016.1251537. Epub 2016 Nov 18. Review.

8.

Live attenuated influenza virus vaccines: new options for the prevention of influenza.

Nichol KL.

Vaccine. 2001 Aug 14;19(31):4373-7. Review.

PMID:
11483261
9.

Influenza vaccines in immunosuppressed adults with cancer.

Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M.

Cochrane Database Syst Rev. 2013 Oct 29;(10):CD008983. doi: 10.1002/14651858.CD008983.pub2. Review.

PMID:
24166741
10.

Influenza vaccines in low and middle income countries: a systematic review of economic evaluations.

Ott JJ, Klein Breteler J, Tam JS, Hutubessy RC, Jit M, de Boer MR.

Hum Vaccin Immunother. 2013 Jul;9(7):1500-11. doi: 10.4161/hv.24704. Epub 2013 May 31. Review.

11.

Influenza cost and cost-effectiveness studies globally--a review.

Peasah SK, Azziz-Baumgartner E, Breese J, Meltzer MI, Widdowson MA.

Vaccine. 2013 Nov 4;31(46):5339-48. doi: 10.1016/j.vaccine.2013.09.013. Epub 2013 Sep 19. Review.

PMID:
24055351
12.

Antiviral agents for influenza: a comparison of cost-effectiveness data.

Lynd LD, Goeree R, O'Brien BJ.

Pharmacoeconomics. 2005;23(11):1083-106. Review.

PMID:
16277546
13.

Influenza vaccination for healthcare workers who care for people aged 60 or older living in long-term care institutions.

Thomas RE, Jefferson T, Lasserson TJ.

Cochrane Database Syst Rev. 2016 Jun 2;(6):CD005187. doi: 10.1002/14651858.CD005187.pub5. Review.

PMID:
27251461
14.

Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies.

Jit M, Newall AT, Beutels P.

Hum Vaccin Immunother. 2013 Apr;9(4):834-40. doi: 10.4161/hv.23637. Epub 2013 Jan 28. Review.

15.

Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50- to 64-year age group.

Newall AT, Kelly H, Harsley S, Scuffham PA.

Pharmacoeconomics. 2009;27(6):439-50. doi: 10.2165/00019053-200927060-00001. Review.

PMID:
19640008
16.

A systematic review of the health economic consequences of quadrivalent influenza vaccination.

de Boer PT, van Maanen BM, Damm O, Ultsch B, Dolk FCK, Crépey P, Pitman R, Wilschut JC, Postma MJ.

Expert Rev Pharmacoecon Outcomes Res. 2017 Jun;17(3):249-265. doi: 10.1080/14737167.2017.1343145. Epub 2017 Jun 28. Review.

PMID:
28613092
17.

The impact of influenza on working days lost: a review of the literature.

Keech M, Beardsworth P.

Pharmacoeconomics. 2008;26(11):911-24. Review.

PMID:
18850761
18.

Prevention and control of influenza in persons with chronic obstructive pulmonary disease.

Plans-Rubió P.

Int J Chron Obstruct Pulmon Dis. 2007;2(1):41-53. Review.

19.

Evaluating the impact of influenza vaccination. A North American perspective.

Fedson DS.

Pharmacoeconomics. 1996;9 Suppl 3:54-61. Review.

PMID:
10160488
20.

Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.

Postma MJ, Baltussen RM, Heijnen ML, de Berg LT, Jager JC.

Drugs Aging. 2000 Sep;17(3):217-27. Review.

PMID:
11043820

Supplemental Content

Support Center